This article is more than 5 years old. Information may no longer be current.

Allegro Ophthalmics to begin two phase 2 studies of integrin peptide therapy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Food and Drug Administration approved an investigational new drug application from Allegro Ophthalmics to begin two phase 2 studies of an integrin peptide therapy for patients with wet age-related macular degeneration or symptomatic vitreomacular traction, according to a news release.

These will be the fifth and sixth studies of ALG-1001 integrin peptide therapy.

Two completed phase 1 trials involved monotherapy studies in wet AMD and diabetic macular edema, and two phase 1b/2a studies, with one being a combination study in DME, are in progress, the release said.